Prelude Capital Management’s Sabra Healthcare REIT SBRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-17,780
Closed -$342K 1496
2026
Q1
$342K Buy
+17,780
New +$350K 0.03% 655
2019
Q4
Sell
-8,767
Closed -$201K 2201
2019
Q3
$201K Sell
8,767
-9,563
-52% -$204K 0.01% 763
2019
Q2
$361K Buy
18,330
+8,794
+92% +$171K 0.02% 558
2019
Q1
$186K Buy
9,536
+4,106
+76% +$77.8K 0.01% 733
2018
Q4
$89K Buy
+5,430
New +$109K 0.01% 969
2018
Q2
Sell
-17,624
Closed -$311K 1906
2018
Q1
$311K Buy
17,624
+13,796
+360% +$243K 0.02% 578
2017
Q4
$72K Sell
3,828
-46,505
-92% -$925K 0.01% 866
2017
Q3
$1.1M Buy
+50,333
New +$1.14M 0.1% 225
2016
Q3
Sell
-3,600
Closed -$74K 1787
2016
Q2
$74K Buy
+3,600
New +$75K 0.01% 863
2015
Q3
Sell
-38,300
Closed -$986K 1742
2015
Q2
$986K Buy
+38,300
New +$1.09M 0.14% 180
2015
Q1
Sell
-18,800
Closed -$571K 2144
2014
Q4
$571K Sell
18,800
-15,200
-45% -$419K 0.08% 271
2014
Q3
$827K Buy
34,000
+9,000
+36% +$250K 0.12% 216
2014
Q2
$718K Buy
+25,000
New +$726K 0.1% 268

Other funds holding SBRA

Prelude Capital Management's SBRA Position: Q2 2026 in Review

Prelude Capital Management sold out of Sabra Healthcare REIT (SBRA) in Q2 2026, closing a stake of 17,780 shares — an estimated $342K sold.

Prelude Capital Management first reported a position in SBRA in Q2 2014 and held it in 13 quarters. The position peaked at $1.1M in Q3 2017. 465 funds tracked by Wall St. Rank hold SBRA as of Q2 2026.

  • Prelude Capital Management reported no remaining Sabra Healthcare REIT position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 17,780 Sabra Healthcare REIT shares in Q2 2026, an estimated $342K.
  • Prelude Capital Management first reported a position in Sabra Healthcare REIT in Q2 2014 and held it in 13 quarters.
  • Prelude Capital Management's Sabra Healthcare REIT position peaked at $1.1M in Q3 2017.
  • 465 funds tracked by Wall St. Rank held Sabra Healthcare REIT as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.